OR WAIT null SECS
October 22, 2025
Article
A recent study highlights correlations between later healing, triglyceride levels, and total cholesterol in patients receiving MH.
October 11, 2025
A pooled cohort analysis of the phase 3 BROOKLYN and BROADWAY trials spotlighted obicetrapib’s impact on patients at risk of cardiovascular mortality.
October 06, 2025
Read about groundbreaking FDA decisions, exciting new heart failure research, and more.
September 26, 2025
This FDA News Month in Review provides a round-up of regulatory decisions from September 2025.
The extended indication includes children 1 to < 5 years of age with homozygous familial hypercholesterolemia.
September 25, 2025
Despite the global prevalence of hypercholesterolemia, only 11% of children receive lipid screening, leaving many cases undiagnosed.
September 23, 2025
New research supports fimasartan, atorvastatin, and ezetimibe combination to blood pressure and cholesterol levels.
September 03, 2025
A recap 8 clinical trials in cardiovascular care to know from the European Society of Cardiology Congress 2025.
Patients with hypercholesterolemia on individualized maximally tolerated dose of statins achieved guideline-recommended LDL-C levels on inclisiran.
September 02, 2025
Merck’s investigational oral PCSK9 inhibitor reduced LDL-C, non-HDL-C, ApoB, and LP(a) significantly compared to placebo after 24 weeks.
